restricting the use of Trovan (trovafloxacin)

July 1999

The FDA is restricting the use of Trovan (trovafloxacin)...too many cases of severe hepatotoxicity.

Since Trovan came out last year, there have been over 100 reports of hepatotoxicity...including 6 deaths.

Now the FDA recommends Trovan ONLY for patients with potentially life-threatening infections...who begin therapy in hospitals or long-term care facilities.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote